US · SNN · MEDICAL - DEVICES
Smith & Nephew plc (SNN) intrinsic value and stock valuation
$29.83as of 2026-11-21 · Mkt cap 12.65B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Smith & Nephew plc DCF and intrinsic value
InvestorsCraft values SNN with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from SNN’s statements →
Smith & Nephew plc Graham Number
Graham Number: $19.90d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Centene Corp. (CNC) $63.78
- Royalty Pharma plc (RPRX) $68.45
- Tenet Healthcare Corporation (THC) $263.19
- Zimmer Biomet Holdings, Inc. (ZBH) $101.10
- Medpace Holdings, Inc. (MEDP) $610.54
- Neurocrine Biosciences, Inc. (NBIX) $150.57
- The Cooper Companies, Inc. (COO) $58.88
- Fresenius Medical Care AG & Co. KGaA (FMS) $20.44
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.16B | $5.81B | $5.55B | $5.22B | $5.21B |
| Operating income | $794M | $657M | $425M | $450M | $593M |
| Net income | $625M | $412M | $263M | $223M | $524M |
| EPSd | $1.43M | $940K | $1.2M | $509.7K | $1.19M |
| Operating cash flow | $1.29B | $987M | $608M | $468M | $877M |
| Capital expenditure | -$-433M | -$-381M | -$-427M | -$-358M | -$-408M |
| Free cash flow | $852M | $606M | $181M | $110M | $469M |
| Total assets | $10.5B | $10.4B | $9.99B | $9.97B | $10.9B |
| Total debt | $3.33B | $3.32B | $3.08B | $2.87B | $3.34B |
| Net debt | $2.77B | $2.7B | $2.78B | $2.52B | $2.05B |
| Total equity | $5.29B | $5.27B | $5.22B | $5.26B | $5.57B |
| Cash and short-term investments | $557M | $619M | $302M | $350M | $1.29B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.16B | $5.81B | $5.55B | $5.22B | $5.21B |
| Cost of revenue | $1.96B | $1.73B | $1.65B | $1.52B | $1.51B |
| Gross profit | $4.21B | $4.08B | $3.9B | $3.7B | $3.7B |
| Research and development expenses | $346M | $343M | $339M | $345M | $356M |
| Selling, general and administrative expenses | $3.04B | $2.9B | $2.83B | $2.71B | $2.64B |
| Other expenses | $31M | $175M | $297M | $198M | $112M |
| Operating expenses | $3.41B | $3.42B | $3.47B | $3.25B | $3.11B |
| Cost and expenses | $5.37B | $5.15B | $5.12B | $4.77B | $4.62B |
| Interest income | $28.1M | $24M | $34.1M | $14M | $6M |
| Interest expense | $141.3M | $150.1M | $132.5M | $80M | $80M |
| Depreciation and amortization | $459M | $449M | $473M | $492M | $507M |
| Ebitda | $1.34B | $1.34B | $1.21B | $1.15B | $1.22B |
| Operating income | $794M | $657M | $425M | $450M | $593M |
| Total other income/expenses, net | -$-15M | -$-159M | -$-135M | -$-215M | -$-7M |
| Income before tax | $779M | $498M | $290M | $235M | $586M |
| Income tax expense | $154M | $86M | $27M | $12M | $62M |
| Net income | $625M | $412M | $263M | $223M | $524M |
| Weighted average shares outstanding | $433.4M | $438.3M | $217.8M | $437.6M | $438.5M |
| Weighted average diluted shares outstanding | $436.5M | $438.3M | $218.4M | $437.6M | $438.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $557M | $619M | $302M | $350M | $1.29B |
| Net receivables | $1.43B | $1.21B | $1.06B | $1.03B | $971M |
| Inventory | $2.12B | $2.39B | $2.4B | $2.21B | $1.84B |
| Total current assets | $4.1B | $4.42B | $4.03B | $3.86B | $4.42B |
| Property, plant and equipment, net | $1.64B | $1.42B | $1.47B | $1.46B | $1.51B |
| Goodwill and intangible assets | $3.99B | $4.06B | $4.1B | $4.27B | $4.39B |
| Long-term investments | $151M | $16M | $24M | $58M | $380M |
| Total non-current assets | $6.35B | $5.93B | $5.96B | $6.11B | $6.5B |
| Total assets | $10.5B | $10.4B | $9.99B | $9.97B | $10.9B |
| Accounts payable | $1.16B | $1.08B | $1.02B | $1.03B | $1.04B |
| Short-term debt | $150M | $63M | $765M | $160M | $491M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $1.6B | $1.53B | $2.27B | $1.72B | $2.13B |
| Long-term debt | $3.18B | $3.26B | $2.32B | $2.71B | $2.85B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $3.57B | $3.56B | $2.5B | $2.99B | $3.22B |
| Capital lease obligations | $216M | $196M | $199M | $196M | $197M |
| Total liabilities | $5.17B | $5.09B | $4.77B | $4.71B | $5.35B |
| Common stock | $175M | $175M | $175M | $175M | $177M |
| Retained earnings | $5.32B | $5.02B | $4.91B | $5.03B | $5.23B |
| Accumulated other comprehensive income (loss) | $20M | $0.00 | -$-385M | -$-439M | -$-328M |
| Total equity | $5.29B | $5.27B | $5.22B | $5.26B | $5.57B |
| Total investments | $151M | $16M | $24M | $58M | $380M |
| Total debt | $3.33B | $3.32B | $3.08B | $2.87B | $3.34B |
| Net debt | $2.77B | $2.7B | $2.78B | $2.52B | $2.05B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $625M | $412M | $263M | $223M | $524M |
| Depreciation and amortization | $573M | $555M | $527M | $548M | $563M |
| Stock-based compensation | $43M | $40M | $39M | $40M | $41M |
| Change in working capital | $33M | -$-123M | -$-227M | -$-510M | -$-232M |
| Accounts receivable | -$-175M | -$-81M | -$-49M | -$-103M | -$-81M |
| Inventory | $208M | -$-42M | -$-178M | -$-407M | -$-151M |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | $1.29B | $987M | $608M | $468M | $877M |
| Investments in property, plant and equipment | -$-433M | -$-381M | -$-427M | -$-358M | -$-408M |
| Acquisitions, net | -$-9M | -$-186M | -$-21M | -$-113M | -$-285M |
| Net cash used for investing activities | -$-406M | -$-569M | -$-448M | -$-472M | -$-691M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-502M | $0.00 | $0.00 | -$-158M | $0.00 |
| Dividends paid | -$-330M | -$-327M | -$-327M | -$-327M | -$-329M |
| Net cash used for financing activities | -$-955M | -$-86M | -$-200M | -$-926M | -$-645M |
| Net change in cash | -$-62M | $317M | -$-44M | -$-941M | -$-466M |
| Cash at end of period | $557M | $617M | $300M | $344M | $1.29B |
| Operating cash flow | $1.29B | $987M | $608M | $468M | $877M |
| Capital expenditure | -$-433M | -$-381M | -$-427M | -$-358M | -$-408M |
| Free cash flow | $852M | $606M | $181M | $110M | $469M |
Line items
Line items
Line items
About Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
- CEO
- Deepak S Nath
- Employees
- 18.36K
- Beta
- 0.69
Explore
Frequently asked questions
What is the intrinsic value of Smith & Nephew plc (SNN)?
Smith & Nephew plc (SNN) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is SNN undervalued?
SNN trades at a price of $29.83 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.